MAETZOLD DEREK J 4

What Happened
Derek J. Maetzold, President & CEO and a director of Castle Biosciences (CSTL), exercised vested options covering 6,214 shares at an exercise price of $2.39 per share (total exercise cost about $14,852) on June 1, 2026. He sold a total of 9,836 shares in open-market transactions that same day for aggregate proceeds of approximately $205,148 (weighted-average sale price $20.86).

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (timely).
• Options exercised: 6,214 shares at $2.39 per share (codes: M). Options are fully vested (footnote F12).
• Open-market sales: 9,836 shares sold (code: S) for total proceeds ≈ $205,148; weighted-average sale price $20.86; trade prices ranged $20.47–$21.175 (footnote F2).
• Some derivative entries in the filing show $0 disposals tied to the option conversions (accounting for the exercise/conversion).
• Transactions were made pursuant to a Rule 10b5-1 trading plan adopted Dec 3, 2025 (footnote F1).
• Several footnotes (F3–F11) indicate portions of holdings are held in family trusts for which Maetzold is trustee or beneficiary.
• Shares owned after the transactions are not specified in the provided excerpt.

Context
The filing shows an option exercise combined with immediate open-market sales under a pre-established 10b5-1 plan. Because the number of shares sold exceeds the shares acquired via exercise, some sales were of previously held shares. Exercises and subsequent sales under a 10b5-1 plan are commonly routine and do not, by themselves, indicate a change in the insider’s view of the company.